Globus Medical Files 8-K on Material Agreement
Ticker: GMED · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1237831
| Field | Detail |
|---|---|
| Company | Globus Medical Inc (GMED) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001, $5.85, $15 million, $10 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
Globus Medical signed a material definitive agreement, filing an 8-K on Feb 6, 2025.
AI Summary
Globus Medical, Inc. filed an 8-K on February 6, 2025, reporting on a material definitive agreement. The filing also included Regulation FD disclosures and other events, along with financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Audubon, PA.
Why It Matters
This 8-K filing indicates a significant development for Globus Medical, Inc., likely involving a new contract or partnership that could impact its business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this summary filing.
Key Players & Entities
- GLOBUS MEDICAL INC (company) — Registrant
- February 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214 (address) — Address of principal executive offices
- (610) 930-1800 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement filed by Globus Medical, Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary information.
When was this 8-K filing submitted?
The 8-K filing was submitted on February 6, 2025.
Where are Globus Medical, Inc.'s principal executive offices located?
Globus Medical, Inc.'s principal executive offices are located at 2560 General Armistead Avenue, Audubon, PA 19403-5214.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What other types of information are included in this 8-K filing besides the material agreement?
The filing also includes Regulation FD disclosures, other events, and financial statements and exhibits.
Filing Stats: 2,027 words · 8 min read · ~7 pages · Grade level 15.6 · Accepted 2025-02-06 16:54:58
Key Financial Figures
- $0.001 — , each share of common stock, par value $0.001 per share, of Nevro ("Nevro Common Stoc
- $5.85 — t to receive cash in an amount equal to $5.85 per share of Nevro Common Stock. Cond
- $15 million — ke a payment to Globus Medical equal to $15 million if the Merger Agreement is terminated i
- $10 million — ke a payment to Globus Medical equal to $10 million if Nevro's stockholders do not affirmat
Filing Documents
- d849414d8k.htm (8-K) — 40KB
- d849414dex21.htm (EX-2.1) — 457KB
- d849414dex101.htm (EX-10.1) — 38KB
- d849414dex991.htm (EX-99.1) — 22KB
- g849414dsp1a.jpg (GRAPHIC) — 4KB
- g849414dsp1b.jpg (GRAPHIC) — 3KB
- 0001193125-25-021848.txt ( ) — 816KB
- gmed-20250206.xsd (EX-101.SCH) — 3KB
- gmed-20250206_lab.xml (EX-101.LAB) — 17KB
- gmed-20250206_pre.xml (EX-101.PRE) — 11KB
- d849414d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 2.1 Agreement and Plan of Merger, dated as of February 6, 2025, by and among Nevro Corp., Globus Medical, Inc. and Palmer Merger Sub, Inc.* 10.1 Voting and Support Agreement, dated as of February 6, 2025, by and among Globus Medical, Inc., Nevro Corp., and other signatories thereto.* 99.1 Press Release, dated February 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission; provided, that the registrant may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished. * * * SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLOBUS MEDICAL, INC. (Registrant) Dated: February 6, 2025 By: /s/ Keith Pfeil Keith Pfeil Chief Financial Officer Chief Operating Officer Chief Accounting Officer Executive Vice President (Principal Financial Officer)